During treatment, ~40% of patients will develop rapidly-evolving leukocytosis (may be associated with higher risk of life-threatening complications). Elevated liver function test results occur in 50% to 60% of patients during treatment. Up to 60% of patients experienced hypercholesterolemia or hypertriglyceridemia (reversible upon completion of treatment). Patients with acute promyelocytic leukemia are at high risk and can have severe adverse reactions to tretinoin. About 25% of patients with acute promyelocytic leukemia and treated with tretinoin experienced retinoic acid-acute promyelocytic leukemia syndrome, characterized by fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates and pleural or pericardial effusions, edema, and hepatic, renal, and/or multiorgan failure; occasionally accompanied by impaired myocardial contractility and episodic hypotension. Retinoids associated with pseudotumor cerebri (benign intracranial hypertension), especially in children. Concurrent use of other drugs associated with this effect may increase risk.